CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement option grant on February 16, 2026 to a newly hired employee.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement option grant on February 16, 2026 to a newly hired employee. The company granted a non-qualified stock option for 8,000 shares with a 10-year term and an exercise price of $3.85, equal to the closing price on the grant date.
The option vests over four years: 25% on the first anniversary and the remainder in 36 equal monthly installments, subject to continued service, under an Inducement Option Award Agreement.
Details
News Market Reaction – CAMP
On Feb 23, the first trading day after this news, CAMP closed 4.15% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- Option shares
- 8,000 shares
- Non-qualified stock option inducement grant
- Exercise price
- $3.85 per share
- Equal to CAMP4’s closing price on Feb 16, 2026 grant date
- Option term
- 10 years
- Term of the inducement stock option
- Vesting cliff
- 25%
- Vests on one-year anniversary of employment start
- Vesting duration
- 4 years
- Overall vesting period for the inducement option
- Monthly installments
- 36 installments
- Remaining option vesting after first year
- Grant date
- February 16, 2026
- Date the inducement option was granted
Historical Context
-
Single-employee inducement option for 8,000 shares with 10-year term.
-
Planned corporate update at J.P. Morgan Healthcare Conference.
-
Pricing of 5,000,000-share offering at $6.00 for $30M gross proceeds.
-
Strategic ASO collaboration with GSK with $17.5M upfront and milestones.
-
Board-approved inducement options totaling 92,000 shares to four new hires.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock option financial
exercise price financial
vesting financial
inducement option award agreement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Inducement Grant has a ten-year term and an exercise price per share of
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.